RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:This is what is actually happeningCXR is trading at the same ev/ebitda multiple to Horizon Pharma. So there is zero premium in the share price for a potential transaction. Remember, CXR should generate about $6.50 per share U.S. In free cash flow this year.